<DOC>
	<DOCNO>NCT00003810</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine docetaxel treat patient locally advanced metastatic cancer pancreas .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Locally Advanced Metastatic Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate patient pancreatic adenocarcinoma treat combination gemcitabine docetaxel . II . Determine toxicity profile combination therapy patient . III . Assess survival rate patient . OUTLINE : Patients receive docetaxel IV 1 hour follow gemcitabine IV 30 minute . Patients receive treatment every week 8 week ( 4 course ) . Patients may continue treatment absence unacceptable toxicity disease progression . Patients follow every 12 week death . PROJECTED ACCRUAL : This study accrue approximately 10 patient per month maximum 33 patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma poorly differentiate carcinoma pancreas Metastatic disease least 1 bidimensionally measurable lesion OR Locally advance disease either recurrent amenable surgery Measurable disease outside prior radiation port disease progression within port PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1500/mm3 Platelet count least 125,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great 2.5 time ULN ( less 3 time ULN liver metastasis ) Renal : Creatinine great ULN Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease At least 1 year since prior adjuvant chemotherapy Prior chemoradiotherapy initial therapy allow Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics See Chemotherapy At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>